Life Science Investing Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
Life Science Investing Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer Annual Meeting
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
